AAM Commends Q1/Q2 House Bill Reintroduction
Reps. Dunn and Mullin bill will cut red tape, bring lower-cost medicines to patients faster, and save more than $800 million over ten years WASHINGTON (March 7, 2025) — The Association for Accessible Medicines today applauded the reintroduction of Q1/Q2 legislation in the U.S. House of Representatives by Congressmen Dunn of Florida and Mullin of […]
AAM Applauds House Passage of the CREATES Act
WASHINGTON DC (December 17, 2019) –AAM applauds passage of the CREATES Act, which will lower drug prices for patients through increased competition and by stopping the abuse of FDA’s safety programs and non-FDA mandated closed distribution systems. With the support of more than 90 organizations, this bipartisan, market-based solution will reduce spending on prescription drugs […]
CREATES ACT – It’s Time to Level the Playing Field
Competition is what makes markets work. It’s what keeps prices down. So when brand pharmaceutical companies tilt the playing field, drugs become less affordable and less accessible. The bipartisan CREATES Act (S. 974/H.R. 2212) would level the field, saving patients billions. Share this video and let’s team up to tackle high drug costs for patients! […]
The CREATES Act Passed! — #PassedCREATES
The CREATES Act passed! Patients will now score greater savings and increased access to #generic and #biosimilar medicines. Join us in thanking all who have advocated for its passage. Learn more: http://bit.ly/PassedCREATESRelease
AAM – Your Generics & Biosimilars Industry
The generic and biosimilar industry is an American success, bringing prices down and making people healthier. The Association for Accessible Medicines and its members devise patient-centered solutions in a market-driven environment. Generic medicines comprise nearly 90% of all prescriptions filled in the United States every year yet represent only 27% of total drug costs. Over […]
AAM Statement on House Energy & Commerce Passage of the CREATES Act
WASHINGTON, DC (April 3, 2019) – The Association for Accessible Medicines welcomes today’s unanimous 51-0 passage of the CREATES Act by the House Energy and Commerce Committee. We commend the leadership of Chairman Frank Pallone (D-NJ), Ranking Member Greg Walden (R-OR), Health Subcommittee Chair Anna Eshoo (D-CA) and Health Subcommittee Ranking Member Michael Burgess (R-TX) […]
Statement from the Association for Accessible Medicines on the Introduction of the CREATES Act
WASHINGTON, DC (February 8, 2019) — The high price of prescription drugs is the number one domestic policy issue in this country, and the CREATES Act is a bipartisan solution that will address some of the anticompetitive tactics that drive prices ever-higher. CREATES has been studied, debated and voted out of committee. Now it is time […]
What They Are Saying – Blocking Access to Samples
STAKEHOLDERS David Mitchell, Patients for Affordable Drugs Testimony, House Oversight Committee, March 22, 2017 “Of course, during this same period, Celgene was doing its best to delay generic versions of the drug by hiding behind its restricted distribution system and REMS—refusing to give samples to generic drug makers. Here’s what that meant for me: My […]
Group Letter in Support of CREATES Act
April 27, 2017 The Honorable Chuck Grassley Chairman The Honorable Patrick Leahy The Honorable Tom Marino The Honorable David Cicilline Dear Senators Grassley and Leahy, and Representatives Marino and Cicilline: As stakeholders firmly committed to fostering patient access to affordable medicines and pharmaceutical competition, we would like to thank […]
Restricted Access Drug Programs Impeding Patient Access to Generic Drugs: Myths and Facts Regarding Maine LD 1280
Brand Manufacturers are Blocking Competition Through Restricted Distribution Channels In order to receive approval from the U.S. Food and Drug Administration (FDA), generic and biosimilar drug manufacturers are required to demonstrate that their products are therapeutically equivalent or highly similar to their brand counterparts by conducting tests using samples of the brand product. Increasingly, brand […]
REMS and Restricted Distribution Programs
Alex Brill June 2017 The sustained concern over high drug prices has led policymakers to identify undue barriers to generic entry as a contributing factor. One such barrier is brand drug manufacturers’ misuse of Risk Evaluation and Mitigation Strategy (REMS) and other restricted access programs to block generic competition. This study explains how REMS programs […]
Using Safety Programs to Protect Profits, Not Patients
Patient safety is our industry’s top priority. FDA-mandated Patient safety programs are the guardrails of our industry. These programs protect patients and the trust they put in medicines by ensuring the benefits of medications outweigh potential risks. Unfortunately, some brand companies have engaged in tactics that abuse these patient safety programs. These abuses cost patients […]
